NCT05857306 is a NA clinical trial of Olvanil in Obesity, sponsored by University of Guadalajara.

Who is sponsoring NCT05857306?

NCT05857306 is sponsored by University of Guadalajara.

What drugs are being tested in NCT05857306?

Interventions in NCT05857306: Olvanil, Placebo.

Is NCT05857306 still recruiting?

NCT05857306 is currently status unknown. Last updated 12 May 2023.

Last reviewed 2023-05-12 · How we verify

NCT05857306

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Olvanil Supplementation on Clinical, Biochemical and Anthropometric Parameters in Obese Adults

Status unknown NA Last updated 12 May 2023

What this trial tests

NA trial testing Olvanil in Obesity in 56 participants. Status unknown.

Timeline

20 February 2023

Primary endpoint
31 July 2023

31 July 2023

Quick facts

Lead sponsor	University of Guadalajara
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	56
Start date	20 February 2023
Primary completion	31 July 2023
Estimated completion	31 July 2023
Sites	2 locations across Mexico

Drugs / interventions tested

Olvanil — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

University of Guadalajara

Who can join

Adults 25 to 59, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Capsaicinoids are defined as alkaloid compounds of the Capsicum genus, they are characterised by the pungent flavor of chili. About the Capsicum genus, there are more than 20 known compounds, including dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin and homocapsaicin. Capsaicin is the most popular compound in the biotechnological food industries. Recent studies has demonstrated the benefits of capsaicin in weight loss, however, the use of this molecule is limited given its high pungent capacity. Pungency develops due to the high affinity of capsaicin for the transient vanilloid potential receptor type 1 (TRPV1), which is primarily responsible for the transmission of pain. In order to eliminate pungency, capsaicin analogs have been developed, such as olvanil, this can become an alternative for its biotechnological and pharmaceutical purposes as an antiobesogenic treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other University of Guadalajara trials

Trials by the same sponsor.

NCT06915701 — "Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis" · Phase 2, PHASE3 · recruiting
NCT07487623 — Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chron · NA · recruiting
NCT07056712 — Effect of Fenugreek Seed Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion · NA · not yet recruiting
NCT07408947 — Clinical Severity in Scorpion Envenomation: Home Remedies, Delay to Medical Care, and Antivenom Dosing Strategies in an · completed
NCT06829186 — The Effect of Curcumin on Inflammatory Markers in Hemodialysis Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05857306 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Guadalajara
Last refreshed: 12 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05857306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing